Biotech · Private company · Boston, MA, US
EIP Pharma Inc
Track this companyFree. Adds EIP Pharma Inc to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- neflamapimodPhase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- NeflamapimodPhase 2 · Dementia With Lewy BodiesClinicalTrials.gov · fetched Nov 12, 2026
- NeflamapimodPhase 2 · Dementia With Lewy Bodies (DLB)ClinicalTrials.gov · fetched Nov 12, 2026
- NeflamapimodPhase 2 · Nonfluent Variant Primary Progressive Aphasia (nfvPPA)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Clinical Study of Neflamapimod in Patients With Primary Progressive AphasiaPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 2, 2025ClinicalTrials.gov NCT07033481 · fetched Nov 12, 2026
- RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy BodiesPHASE2 · COMPLETED · started May 1, 2023ClinicalTrials.gov NCT05869669 · fetched Nov 12, 2026
- Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy BodiesPHASE2 · COMPLETED · started Sep 30, 2019ClinicalTrials.gov NCT04001517 · fetched Nov 12, 2026
- Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's DiseasePHASE2 · COMPLETED · started Dec 29, 2017ClinicalTrials.gov NCT03402659 · fetched Nov 12, 2026
NIH awards3
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)Fiscal year 2025 · $6.1MNIH RePORTER 5R01AG080536-03 · fetched Nov 12, 2026
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)Fiscal year 2024 · $250KNIH RePORTER 3R01AG080536-02S1 · fetched Nov 12, 2026
- A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)Fiscal year 2024 · $8.1MNIH RePORTER 5R01AG080536-02 · fetched Nov 12, 2026